Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1047 • ACR Convergence 2024
Impact of Treatment Switching on Adherence in Members with Rheumatoid Arthritis, Psoriatic Arthritis, or Systemic Lupus Erythematosus
Jean Park¹, Cliff Rutter², Elisea Avalos-Reyes³, Mary Anderson⁴, Will Cavers⁵, Dorothea Verbrugge⁶ and Kjel Johnson⁷, ¹CVS Health, Hartford, CT, ²CVS Health, Fair Oaks Ranch, TX, ³CVS Health, Highland Village, TX, ⁴CVS Health, Irving, TX, ⁵CVS Health, Palm Beach Gardens, ⁶CVS Health, Salt Lake City, ⁷CVS Health, Tampa
Background/Purpose: Switching treatment from conventional to biologic disease-modifying antirheumatic drugs (DMARDs) is a common practice for managing autoimmune diseases such as rheumatoid arthritis (RA), psoriatic…
Abstract Number: 1316 • ACR Convergence 2024
Dual Therapy with a JAKi and bDMARD in Patients with Standard Treatment Resistant Rheumatic Disease: A Case Series
Bella Garg¹, John Antowan² and daniel Furst³, ¹Centinela Hospital Medical Center, Inglewood, CA, ²UCLA, Los Angeles, ³Pacific Arthritis Center, Inglewood
Background/Purpose: Due to concerns about side effects, combined JAK inhibitors (JAKi) and biologic DMARDs (bDMARDs) have not been recommended for rheumatologic conditions. However, combining them…
Abstract Number: 1340 • ACR Convergence 2024
Characteristics and Long-term Outcomes of Patients with Rheumatoid Arthritis and Concurrent Calcium Pyrophosphate Deposition Disease
Natalie Schanzer¹, Ted Mikuls², Bryant England², Katherine Wysham³, Jorge Rojas⁴, Sauer brian⁵, Beth Wallace⁶, Rachel Elam⁷, Andreas Reimold⁸, Gail Kerr⁹, John Richards¹⁰, Gary Kunkel¹¹, Iris Lee¹², Isaac Smith¹³, Paul Monach¹⁴, grant Cannon¹⁵ and Joshua Baker¹⁶, ¹Perelman School of Medicine at University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Seattle VA, Mexico, Mexico, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁷Augusta University, Evans, GA, ⁸Dallas VA Medical Center, Dallas, TX, ⁹Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹⁰Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹¹University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ¹²Washington University in St Louis, Saint Louis, MO, ¹³Duke University Hospital, Durham, NC, ¹⁴VA Boston Healthcare System, Boston, MA, ¹⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Calcium pyrophosphate deposition disease (CPPD) is a common crystalline arthritis that can both present alongside rheumatoid arthritis (RA) and, given its similar pattern of…
Abstract Number: 1356 • ACR Convergence 2024
Association Between Vascular Inflammation and Kidney Function in Patients with Rheumatoid Arthritis: Secondary Analysis of TARGET Trial
Sho Fukui¹, Ahmed Tawakol², Wolfgang Winkelmayer³, Leah Santacroce⁴, Jon Giles⁵, Katherine Liao⁴, Joan Bathon⁶ and Daniel Solomon⁷, ¹Brigham and Women's Hospital, Brookline, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Baylor College of Medicine, Houston, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Cedars Sinai Medical Center, Los Angeles, CA, ⁶Columbia University, NEW YORK, NY, ⁷Brigham and Women's Hospital, Newton, MA
Background/Purpose: Kidney dysfunction is a common complication in patients with rheumatoid arthritis (RA). More severe disease activity is associated with a larger decline in the…
Abstract Number: 1372 • ACR Convergence 2024
Upadacitinib and Other JAK Inhibitors in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study Clinical Practice.
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Loarce³, Leticia del Olmo Perez⁴, Sara García-Pérez⁵, Guillermo Gonzalez Mozo de Rosales⁶, José Rosas-Gómez de Salazar⁷, Ana Urruticoechea-Arana⁸, Andrea García-Valle⁹, Juan Moreno Morales¹⁰, María Martín López¹¹, Patricia Lopez Viejo¹², Virginia Ruiz-Esquide¹³, Julia Fernandez Melon¹⁴, David Castro-Corredor¹⁵, Ana Fernández-Ortiz¹⁶, Rafael Benito Melero-Gonzalez¹⁷, Carolina Díez Morrondo¹⁸, Desiree Palma¹⁹, Natividad del Val del Amo²⁰, Natalia Mena Vázquez²¹, Alicia García Dorta²², MARÍA JOSÉ PÉREZ GALÁN²³, MARINA SOLEDAD MORENO GARCIA²⁴ and Ricardo Blanco-Alonso²⁵, and on behalf of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴HOSPITAL NUESTRA SEÑORA DEL PRADO, TALAVERA DE LA REINA, Spain, ⁵Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ⁸Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ⁹Hospital General Río Carrión, Palencia, Spain, ¹⁰Hospital Universitario Santa Lucia Cartagena, Murcia, Murcia, Spain, ¹¹General University Hospital of Ciudad Real, Ciudad de México, Spain, ¹²Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹³Hospital Clinic de Barcelona, Barcelona, Spain, ¹⁴Hospital Son Espases, Palma, Spain, ¹⁵General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹⁶Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁷CHU Ourense, O Carballino, Spain, ¹⁸Complejo Asistencial Universitario de Leon, Leon, ¹⁹Hospital Rafael Méndez, Lorca, Murcia, Spain, ²⁰Complejo Hospitalario de Navarra, Pamplona, Spain, ²¹IBIMA, Málaga, Andalucia, Spain, ²²Rheumatologist, La Laguna, Spain, ²³SERVICIO ANDALUZ DE SALUD, GRANADA, Andalucia, Spain, ²⁴Hospital Universitario Miguel Servet, GIJON, Asturias, Spain, ²⁵Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 1390 • ACR Convergence 2024
One-year Real World Evidence Outcomes from the Cohort RADIUS (Real-world Analysis of Upadacitinib in Rheumatoid Arthritis Patients for Improved Understanding and Safety)
Luis Gomez-Lechon Quiros¹, José Miguel Sequí-Sabater², Amalia Rueda³, Costas Torrijo Nerea⁴, Carlos Valera-Ribera⁵, Juan Miguel López-Gómez⁶ and Antonio Alvarez-Cienfuegos⁷, ¹Hospital Francesc de Borja, Valéncia, Spain, ²La Ribera University Hospital, Rheumatology Department, Gandía, Comunidad Valenciana, Spain, ³Hospital General de Valencia, VALENCIA, Comunidad Valenciana, Spain, ⁴Generalitat valenciana, Valencia, Spain, ⁵Hospital Doctor Peset, Valéncia, Comunidad Valenciana, Spain, ⁶Conselleria de Sanitat/Hospital Universitario de Elda, Elda, Comunidad Valenciana, Spain, ⁷Conselleria de Sanitat/Hospital de la Vega Baja, Orihuela, Comunidad Valenciana, Spain
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease that affects the joints and other parts of the musculoskeletal system. Early diagnosis and initiation of…
Abstract Number: 1648 • ACR Convergence 2024
In Vitro Expansion of ACPA-positive B Cells from Rheumatoid Arthritis Patients and Effect of Small Molecule NF-κB Inhibitors on Differentiation and Survival of (Autoreactive) Memory B Cells into Plasma Cells
Giulia Frazzei¹, Ana Merino Vico², Jan Piet van Hamburg², Ronald Van Vollenhoven³ and Sander Tas⁴, ¹Amsterdam University Medical Center, location AMC, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands, ³Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) play a role in rheumatoid arthritis (RA) pathogenesis and are associated with disease severity. Detailed analysis of ACPApos B cells…
Abstract Number: 1719 • ACR Convergence 2024
Cumulative Glucocorticoid Exposure and Major Adverse Cardiovascular Events in a Cohort of Veterans with Rheumatoid Arthritis: A Nested Case-Control Study
Beth Wallace¹, Yuqing Gao², H. Myra Kim³, Bryant England⁴, Sauer brian⁵, grant Cannon⁶, Punyasha Roul⁷, Ted Mikuls⁴, Shirley Cohen-Mekelburg⁸, Daniel Clauw⁹, Wyndy Wiitala², Rodney Hayward¹⁰, Jeremy Sussman¹¹ and Akbar Waljee¹¹, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ³University of Michigan School of Public Health, Ann Arbor, MI, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷UNMC, Omaha, NE, ⁸University of Michigan Department of Internal Medicine, Division of Gastroenterology, Ann Arbor, MI, ⁹University of Michigan, Whitmore Lake, MI, ¹⁰Department of Internal Medicine, University of Michigan; Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI, ¹¹Internal Medicine and Center for Clinical Management Research, Department of Veterans Affairs, VA Ann Arbor Healthcare System, Ann Arbor, MI
Background/Purpose: Three-quarters of RA patients use glucocorticoids (GC) to manage RA symptoms. Our work presented previously suggests recent GC use (up to 2 years prior…
Abstract Number: 1850 • ACR Convergence 2024
Exhausted T-cells Are Increased in Autoimmune Diseases and Predict Response to Anti-TNF in RA and SPA Patients
Samuel Bitoun¹, Marie Naigeon², Matthieu Roulleaux- Dugage², Caroline De Oliveira², Caroline Berthot², Xavier Mariette³, Gaetane Nocturne³ and Nathalie Chaput-Gras², ¹Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ²Laboratoire d'immunomonitoring en Oncologie, INSERM US23, CNRS UMS 3655, Gustave Roussy,, Villejuif, France, ³Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France
Background/Purpose: Exhaustion can occur after prolonged activation of T cells limiting their immunosurveillance function leading to cancer emergence. Among the exhaustion markers expressed on T…
Abstract Number: 1935 • ACR Convergence 2024
Timely Referral of Patients with Inflammatory Rheumatic Diseases to Rheumatology: Validation of a Referral Algorithm with Frontline Physicians
Nelly Ziade¹, Karen Mechleb², Nizar Ani³, avin maroof⁴, ASAL ADNAN RIDHA⁵, Manal El Rakawi⁶, Chafika Haouichat⁶, Bassel Elzorkany⁷, Sherif Gamal⁸, Mariama Erraoui⁹, Manal Al-Mashaleh¹⁰, Fatima Alnaimat¹¹, Basel masri¹², fatemah Baron¹³, Lina El Kibbi¹⁴, Krystel Aouad¹⁵ and Ihsane Hmamouchi¹⁶, and ARCH - ArLAR, ¹Saint-Joseph University, Beirut, Lebanon, ²Saint Joseph University Beirut, Beirut, Lebanon, ³Baghdad College of Medicine, Baghdad, Iraq, ⁴University of Kurdistan Hawler, Erbil, Iraq, ⁵Baghdad Teaching Hospital, baghdad, Iraq, ⁶Djillali Bounaama University Hospital, Algiers, Algeria, ⁷Private (BZRC), Cairo, Egypt, ⁸Cairo University, Cairo, Egypt, ⁹Souss Massa Univeristy, Rabat, Morocco, ¹⁰Royal Medical Services, Amman, Jordan, ¹¹University of Jordan, Amman, Jordan, ¹²Jordan Hospital and Medical Center, Amman, Jordan, ¹³Al-Jahra Hospital, Ministry of Health, Kuwait, Kuwait, ¹⁴Specialized Medical Center, Riyadh, Saudi Arabia, ¹⁵Saint George Hospital University Medical Center, Beirut, Lebanon, ¹⁶Rheumatology Unit, Lalla Aicha Temara Hospital, Temara, Rabat, Morocco
Background/Purpose: Early referral of patients with chronic inflammatory rheumatic diseases (CIRDs) to rheumatology is essential to reduce diagnostic delays and improve long-term prognosis. Referral strategies…
Abstract Number: 2140 • ACR Convergence 2024
Frailty Is Associated with Lower Bone Mineral Density in US Veterans with Rheumatoid Arthritis
Katherine Wysham¹, Hannah Brubeck², Kylie Riggles³, Riley Bass⁴, Elizabeth Wahl², Radhika Narla⁵, Namrata Singh⁶, ariela orkaby⁷, Joshua Baker⁸, Patricia Katz⁹, Dolores Shoback¹⁰ and Jose Garcia¹¹, ¹VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³VA Puget Sound Health Care System, Bellevue, WA, ⁴VA Puget Sound Health Care System, Seattle, ⁵VA Puget Sound Healthcare System, Seattle, WA, Seattle, WA, ⁶University of Washington, Bellevue, WA, ⁷New England VA Geriatric Research Education and Clinical Center/Boston VA/Division of Aging, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁹University of California, San Francisco, San Francisco, CA, ¹⁰San Francisco VA/University of California, San Francisco, San Francisco, CA, ¹¹VA Puget Sound Health Care System/University of Washington, Seattle, WA
Background/Purpose: Frailty represents a state of increased vulnerability to poor outcomes after physiologic stressors, and occurs at higher rates and younger ages in RA. Frailty…
Abstract Number: 2220 • ACR Convergence 2024
Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis
Andrew Price, David Mecham, Zachary Kerosky, Joshua Hunt, Anthony Greco and Michael Loncharich, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose: Seronegative rheumatoid arthritis (SnRA) and undifferentiated arthritis (UA) are heterogeneous conditions that share many clinical features with other systemic rheumatic diseases. Patients initially diagnosed…
Abstract Number: 2237 • ACR Convergence 2024
The Association Between Bariatric Surgery and Incident Rheumatoid Arthritis
Helana Jeries¹, Revital Perlov Gavze², Rula Daood³, Fadi Hassan³, Liat Lev shalem⁴, Ahmad Assalia⁵ and Mohammad E Naffaa³, ¹Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, HaZafon, Israel, ²Maccabi Healthcare Services, Tel Aviv, Israel, ³Rheumatology Unit, Galilee Medical Center, Naharyia, Israel, Naharyia, Israel, ⁴Maccabi Healthcare Services, Tel Aviv, HaMerkaz, Israel, ⁵Rambam Healthcare Campus, Haifa, HaZafon, Israel
Background/Purpose: Obesity is considered a controversial risk factor for developing rheumatoid arthritis (RA), and the association between weight change and RA incidence is inconclusive. The…
Abstract Number: 2256 • ACR Convergence 2024
Depletion of Citrullinated Vimentin-reactive Follicular Helper T Cells with Treatment-induced Remission of Recent-onset Rheumatoid Arthritis When Compared to Non-remission at 6 Months
Jia Yi Hee¹, Hendrik Nel², Yann Abraham³, Katrina Chakradeo⁴, Michelle Roch⁴, Tom Lynch⁵, Lyn March⁵, Mihir Wechalekar⁶, Helen Keen⁷ and Ranjeny Thomas⁸, ¹The University of Queensland, Woolloongabba, Queensland, Australia, ²Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, ³Janssen Research and Development, Beerse, Belgium, ⁴The University of Queensland, Brisbane, Australia, ⁵The University of Sydney, Sydney, New South Wales, Australia, ⁶Flinders Medical Centre, Adelaide, Australia, ⁷Fiona Stanley Hospital, Murdoch, Western Australia, Australia, ⁸University of Queensland, Brisbane, Australia
Background/Purpose: More than 50% of people with new-onset RA may achieve remission within the first year on conventional synthetic (cs)-DMARDs. Sustained remission confers better long-term…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].